Lubiprostone	B:C1684405
Accelerates	O
Intestinal	O
Transit	I:C0232484
and	O
Alleviates	O
Small	O
Intestinal	I:C3160854
Bacterial	I:C3160854
Overgrowth	I:C3160854
in	O
Patients	O
With	O
Chronic	O
Constipation	I:C0401149
.	O

Lubiprostone	O
Accelerates	O
Intestinal	B:C0232484
Transit	I:C0232484
and	O
Alleviates	O
Small	O
Intestinal	I:C3160854
Bacterial	I:C3160854
Overgrowth	I:C3160854
in	O
Patients	O
With	O
Chronic	O
Constipation	I:C0401149
.	O

Lubiprostone	O
Accelerates	O
Intestinal	O
Transit	I:C0232484
and	O
Alleviates	O
Small	B:C3160854
Intestinal	I:C3160854
Bacterial	I:C3160854
Overgrowth	I:C3160854
in	O
Patients	O
With	O
Chronic	O
Constipation	I:C0401149
.	O

Lubiprostone	O
Accelerates	O
Intestinal	O
Transit	I:C0232484
and	O
Alleviates	O
Small	O
Intestinal	I:C3160854
Bacterial	I:C3160854
Overgrowth	I:C3160854
in	O
Patients	O
With	O
Chronic	B:C0401149
Constipation	I:C0401149
.	O

Lubiprostone	B:C1684405
is	O
an	O
effective	O
treatment	O
for	O
chronic	O
constipation	I:C0401149
(	O
chronic	O
constipation	I:C0401149
)	O
.	O

Lubiprostone	O
is	O
an	O
effective	O
treatment	O
for	O
chronic	B:C0401149
constipation	I:C0401149
(	O
chronic	O
constipation	I:C0401149
)	O
.	O

Lubiprostone	O
is	O
an	O
effective	O
treatment	O
for	O
chronic	O
constipation	I:C0401149
(	O
chronic	B:C0401149
constipation	I:C0401149
)	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
lubiprostone	B:C1684405
is	O
through	O
increasing	O
fluid	O
secretion	I:C2263233
and	O
lubrication	O
of	O
the	O
intestinal	O
lumen	I:C0545876
.	O

The	O
mechanism	O
of	O
action	O
of	O
lubiprostone	O
is	O
through	O
increasing	O
fluid	B:C2263233
secretion	I:C2263233
and	O
lubrication	O
of	O
the	O
intestinal	O
lumen	I:C0545876
.	O

The	O
mechanism	O
of	O
action	O
of	O
lubiprostone	O
is	O
through	O
increasing	O
fluid	O
secretion	I:C2263233
and	O
lubrication	O
of	O
the	O
intestinal	B:C0545876
lumen	I:C0545876
.	O

The	O
effects	O
of	O
lubiprostone	B:C1684405
on	O
gastrointestinal	O
transit	I:C0232484
and	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
(	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
)	O
have	O
not	O
been	O
adequately	O
explored	O
.	O

The	O
effects	O
of	O
lubiprostone	O
on	O
gastrointestinal	B:C0232484
transit	I:C0232484
and	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
(	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
)	O
have	O
not	O
been	O
adequately	O
explored	O
.	O

The	O
effects	O
of	O
lubiprostone	O
on	O
gastrointestinal	O
transit	I:C0232484
and	O
small	B:C3160854
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
(	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
)	O
have	O
not	O
been	O
adequately	O
explored	O
.	O

The	O
effects	O
of	O
lubiprostone	O
on	O
gastrointestinal	O
transit	I:C0232484
and	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
(	O
small	B:C3160854
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
)	O
have	O
not	O
been	O
adequately	O
explored	O
.	O

The	O
current	O
study	B:C2603343
was	O
designed	O
to	O
investigate	O
whether	O
lubiprostone	O
(	O
1	O
)	O
alters	O
gastrointestinal	O
transit	I:C0232484
and	O
(	O
2	O
)	O
affects	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
in	O
patients	O
with	O
constipation	O
.	O

The	O
current	O
study	O
was	O
designed	O
to	O
investigate	O
whether	O
lubiprostone	B:C1684405
(	O
1	O
)	O
alters	O
gastrointestinal	O
transit	I:C0232484
and	O
(	O
2	O
)	O
affects	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
in	O
patients	O
with	O
constipation	O
.	O

The	O
current	O
study	O
was	O
designed	O
to	O
investigate	O
whether	O
lubiprostone	O
(	O
1	O
)	O
alters	O
gastrointestinal	B:C0232484
transit	I:C0232484
and	O
(	O
2	O
)	O
affects	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
in	O
patients	O
with	O
constipation	O
.	O

The	O
current	O
study	O
was	O
designed	O
to	O
investigate	O
whether	O
lubiprostone	O
(	O
1	O
)	O
alters	O
gastrointestinal	O
transit	I:C0232484
and	O
(	O
2	O
)	O
affects	O
small	B:C3160854
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
in	O
patients	O
with	O
constipation	O
.	O

The	O
current	O
study	O
was	O
designed	O
to	O
investigate	O
whether	O
lubiprostone	O
(	O
1	O
)	O
alters	O
gastrointestinal	O
transit	I:C0232484
and	O
(	O
2	O
)	O
affects	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
in	O
patients	O
with	O
constipation	B:C0009806
.	O

A	O
total	O
of	O
29	O
female	O
patients	O
(	O
mean	O
age	O
=	O
39	O
years	O
;	O
range	O
:	O
19	O
-	O
64	O
)	O
with	O
chronic	B:C0401149
constipation	I:C0401149
received	O
2	O
weeks	O
of	O
lubiprostone	O
(	O
24mcg	O
b.i.d.	O
,	O
P.O.	O
)	O
.	O

A	O
total	O
of	O
29	O
female	O
patients	O
(	O
mean	O
age	O
=	O
39	O
years	O
;	O
range	O
:	O
19	O
-	O
64	O
)	O
with	O
chronic	O
constipation	I:C0401149
received	O
2	O
weeks	O
of	O
lubiprostone	B:C1684405
(	O
24mcg	O
b.i.d.	O
,	O
P.O.	O
)	O
.	O

Stool	B:C0426740
consistency	I:C0426740
based	O
on	O
Bristol	O
stool	I:C4084861
scale	I:C4084861
and	O
the	O
frequency	O
of	I:C0426642
bowel	I:C0426642
movements	I:C0426642
(	O
bowel	O
movements	I:C0011135
)	O
were	O
recorded	O
.	O

Stool	O
consistency	I:C0426740
based	O
on	O
Bristol	B:C4084861
stool	I:C4084861
scale	I:C4084861
and	O
the	O
frequency	O
of	I:C0426642
bowel	I:C0426642
movements	I:C0426642
(	O
bowel	O
movements	I:C0011135
)	O
were	O
recorded	O
.	O

Stool	O
consistency	I:C0426740
based	O
on	O
Bristol	O
stool	I:C4084861
scale	I:C4084861
and	O
the	O
frequency	B:C0426642
of	I:C0426642
bowel	I:C0426642
movements	I:C0426642
(	O
bowel	O
movements	I:C0011135
)	O
were	O
recorded	O
.	O

Stool	O
consistency	I:C0426740
based	O
on	O
Bristol	O
stool	I:C4084861
scale	I:C4084861
and	O
the	O
frequency	O
of	I:C0426642
bowel	I:C0426642
movements	I:C0426642
(	O
bowel	B:C0011135
movements	I:C0011135
)	O
were	O
recorded	O
.	O

Gastric	O
emptying	O
time	O
,	O
small	O
bowel	O
transit	O
time	O
,	O
colon	B:C0009368
transit	O
time	O
(	O
CTT	O
)	O
,	O
combined	O
small	O
and	I:C0232688
large	I:C0232688
bowel	I:C0232688
transit	I:C0232688
time	I:C0232688
(	O
small	O
and	I:C0232688
large	I:C0232688
bowel	I:C0232688
transit	I:C0232688
time	I:C0232688
)	O
and	O
whole	O
gut	O
transit	O
time	O
were	O
measured	O
using	O
wireless	O
motility	I:C0430022
capsule	I:C0430022
.	O

Gastric	O
emptying	O
time	O
,	O
small	O
bowel	O
transit	O
time	O
,	O
colon	O
transit	O
time	O
(	O
CTT	O
)	O
,	O
combined	O
small	B:C0232688
and	I:C0232688
large	I:C0232688
bowel	I:C0232688
transit	I:C0232688
time	I:C0232688
(	O
small	O
and	I:C0232688
large	I:C0232688
bowel	I:C0232688
transit	I:C0232688
time	I:C0232688
)	O
and	O
whole	O
gut	O
transit	O
time	O
were	O
measured	O
using	O
wireless	O
motility	I:C0430022
capsule	I:C0430022
.	O

Gastric	O
emptying	O
time	O
,	O
small	O
bowel	O
transit	O
time	O
,	O
colon	O
transit	O
time	O
(	O
CTT	O
)	O
,	O
combined	O
small	O
and	I:C0232688
large	I:C0232688
bowel	I:C0232688
transit	I:C0232688
time	I:C0232688
(	O
small	B:C0232688
and	I:C0232688
large	I:C0232688
bowel	I:C0232688
transit	I:C0232688
time	I:C0232688
)	O
and	O
whole	O
gut	O
transit	O
time	O
were	O
measured	O
using	O
wireless	O
motility	I:C0430022
capsule	I:C0430022
.	O

Gastric	O
emptying	O
time	O
,	O
small	O
bowel	O
transit	O
time	O
,	O
colon	O
transit	O
time	O
(	O
CTT	O
)	O
,	O
combined	O
small	O
and	I:C0232688
large	I:C0232688
bowel	I:C0232688
transit	I:C0232688
time	I:C0232688
(	O
small	O
and	I:C0232688
large	I:C0232688
bowel	I:C0232688
transit	I:C0232688
time	I:C0232688
)	O
and	O
whole	O
gut	B:C0699819
transit	O
time	O
were	O
measured	O
using	O
wireless	O
motility	I:C0430022
capsule	I:C0430022
.	O

Gastric	O
emptying	O
time	O
,	O
small	O
bowel	O
transit	O
time	O
,	O
colon	O
transit	O
time	O
(	O
CTT	O
)	O
,	O
combined	O
small	O
and	I:C0232688
large	I:C0232688
bowel	I:C0232688
transit	I:C0232688
time	I:C0232688
(	O
small	O
and	I:C0232688
large	I:C0232688
bowel	I:C0232688
transit	I:C0232688
time	I:C0232688
)	O
and	O
whole	O
gut	O
transit	O
time	O
were	O
measured	O
using	O
wireless	B:C0430022
motility	I:C0430022
capsule	I:C0430022
.	O

The	O
small	B:C3160854
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
status	O
was	O
assessed	O
by	O
the	O
lactulose	O
breath	I:C0344439
test	I:C0344439
.	O

The	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
status	O
was	O
assessed	O
by	O
the	O
lactulose	B:C0344439
breath	I:C0344439
test	I:C0344439
.	O

Data	O
were	O
analyzed	B:C0936012
using	O
Wilcoxon	O
rank	O
,	O
Mann	O
-	O
Whitney	O
U	O
,	O
Spearman׳s	O
rank	O
correlation	O
and	O
Chi-square	O
tests	I:C0008041
.	O

Data	O
were	O
analyzed	O
using	O
Wilcoxon	O
rank	O
,	O
Mann	O
-	O
Whitney	O
U	O
,	O
Spearman׳s	O
rank	O
correlation	O
and	O
Chi-square	B:C0008041
tests	I:C0008041
.	O

Lubiprostone	B:C1684405
significantly	O
softened	O
the	O
stool	O
and	O
increased	O
the	O
frequency	O
of	I:C0426642
BM	I:C0426642
from	O
median	O
of	O
2	O
to	O
4	O
times	O
per	O
week	O
.	O

Lubiprostone	O
significantly	O
softened	O
the	O
stool	B:C0015733
and	O
increased	O
the	O
frequency	O
of	I:C0426642
BM	I:C0426642
from	O
median	O
of	O
2	O
to	O
4	O
times	O
per	O
week	O
.	O

Lubiprostone	O
significantly	O
softened	O
the	O
stool	O
and	O
increased	O
the	O
frequency	B:C0426642
of	I:C0426642
BM	I:C0426642
from	O
median	O
of	O
2	O
to	O
4	O
times	O
per	O
week	O
.	O

The	O
CTT	O
and	O
small	B:C0232688
and	I:C0232688
large	I:C0232688
bowel	I:C0232688
transit	I:C0232688
time	I:C0232688
were	O
significantly	O
shorter	O
in	O
responders	O
to	O
lubiprostone	O
(	O
i.e.	O
,	O
those	O
with	O
≥	O
2	O
times	O
increase	O
in	O
the	O
number	O
of	O
their	O
weekly	O
BM	O
)	O
compared	O
with	O
nonresponders	O
.	O

The	O
CTT	O
and	O
small	O
and	I:C0232688
large	I:C0232688
bowel	I:C0232688
transit	I:C0232688
time	I:C0232688
were	O
significantly	O
shorter	O
in	O
responders	B:C1257890
to	O
lubiprostone	O
(	O
i.e.	O
,	O
those	O
with	O
≥	O
2	O
times	O
increase	O
in	O
the	O
number	O
of	O
their	O
weekly	O
BM	O
)	O
compared	O
with	O
nonresponders	O
.	O

The	O
CTT	O
and	O
small	O
and	I:C0232688
large	I:C0232688
bowel	I:C0232688
transit	I:C0232688
time	I:C0232688
were	O
significantly	O
shorter	O
in	O
responders	O
to	O
lubiprostone	B:C1684405
(	O
i.e.	O
,	O
those	O
with	O
≥	O
2	O
times	O
increase	O
in	O
the	O
number	O
of	O
their	O
weekly	O
BM	O
)	O
compared	O
with	O
nonresponders	O
.	O

The	O
CTT	O
and	O
small	O
and	I:C0232688
large	I:C0232688
bowel	I:C0232688
transit	I:C0232688
time	I:C0232688
were	O
significantly	O
shorter	O
in	O
responders	O
to	O
lubiprostone	O
(	O
i.e.	O
,	O
those	O
with	O
≥	O
2	O
times	O
increase	O
in	O
the	O
number	O
of	O
their	O
weekly	O
BM	B:C0011135
)	O
compared	O
with	O
nonresponders	O
.	O

The	O
CTT	O
and	O
small	O
and	I:C0232688
large	I:C0232688
bowel	I:C0232688
transit	I:C0232688
time	I:C0232688
were	O
significantly	O
shorter	O
in	O
responders	O
to	O
lubiprostone	O
(	O
i.e.	O
,	O
those	O
with	O
≥	O
2	O
times	O
increase	O
in	O
the	O
number	O
of	O
their	O
weekly	O
BM	O
)	O
compared	O
with	O
nonresponders	B:C1257890
.	O

The	O
higher	O
frequency	B:C0426642
of	I:C0426642
BM	I:C0426642
after	O
treatment	O
was	O
significantly	O
correlated	O
with	O
the	O
acceleration	O
of	O
CTT	O
,	O
small	O
and	I:C0232688
large	I:C0232688
bowel	I:C0232688
transit	I:C0232688
time	I:C0232688
and	O
whole	O
gut	O
transit	O
time	O
.	O

The	O
higher	O
frequency	O
of	I:C0426642
BM	I:C0426642
after	O
treatment	O
was	O
significantly	O
correlated	O
with	O
the	O
acceleration	O
of	O
CTT	O
,	O
small	B:C0232688
and	I:C0232688
large	I:C0232688
bowel	I:C0232688
transit	I:C0232688
time	I:C0232688
and	O
whole	O
gut	O
transit	O
time	O
.	O

The	O
higher	O
frequency	O
of	I:C0426642
BM	I:C0426642
after	O
treatment	O
was	O
significantly	O
correlated	O
with	O
the	O
acceleration	O
of	O
CTT	O
,	O
small	O
and	I:C0232688
large	I:C0232688
bowel	I:C0232688
transit	I:C0232688
time	I:C0232688
and	O
whole	O
gut	B:C0699819
transit	O
time	O
.	O

In	O
all	O
,	O
17	O
out	O
of	O
25	O
(	O
68	O
%	O
)	O
patients	O
,	O
who	O
were	O
tested	O
for	O
small	B:C3160854
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
at	O
baseline	O
,	O
were	O
positive	O
.	O

In	O
all	O
,	O
17	O
out	O
of	O
25	O
(	O
68	O
%	O
)	O
patients	O
,	O
who	O
were	O
tested	O
for	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
at	O
baseline	O
,	O
were	O
positive	B:C1446409
.	O

In	O
addition	O
,	O
7	O
out	O
of	O
17	O
(	O
41	O
%	O
)	O
small	B:C3160854
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
-	O
positive	O
patients	O
became	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
-	O
negative	O
after	O
lubiprostone	O
treatment	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
addition	O
,	O
7	O
out	O
of	O
17	O
(	O
41	O
%	O
)	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
-	O
positive	B:C1446409
patients	O
became	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
-	O
negative	O
after	O
lubiprostone	O
treatment	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
addition	O
,	O
7	O
out	O
of	O
17	O
(	O
41	O
%	O
)	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
-	O
positive	O
patients	O
became	O
small	B:C3160854
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
-	O
negative	O
after	O
lubiprostone	O
treatment	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
addition	O
,	O
7	O
out	O
of	O
17	O
(	O
41	O
%	O
)	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
-	O
positive	O
patients	O
became	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
-	O
negative	B:C0205160
after	O
lubiprostone	O
treatment	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
addition	O
,	O
7	O
out	O
of	O
17	O
(	O
41	O
%	O
)	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
-	O
positive	O
patients	O
became	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
-	O
negative	O
after	O
lubiprostone	B:C1684405
treatment	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
chronic	B:C0401149
constipation	I:C0401149
,	O
lubiprostone	O
improves	O
the	O
frequency	O
of	I:C0426642
BMs	I:C0426642
,	O
softens	O
the	O
stool	O
,	O
accelerates	O
intestinal	O
transit	I:C0232484
and	O
decreases	O
accompanying	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
.	O

In	O
chronic	O
constipation	I:C0401149
,	O
lubiprostone	B:C1684405
improves	O
the	O
frequency	O
of	I:C0426642
BMs	I:C0426642
,	O
softens	O
the	O
stool	O
,	O
accelerates	O
intestinal	O
transit	I:C0232484
and	O
decreases	O
accompanying	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
.	O

In	O
chronic	O
constipation	I:C0401149
,	O
lubiprostone	O
improves	O
the	O
frequency	B:C0426642
of	I:C0426642
BMs	I:C0426642
,	O
softens	O
the	O
stool	O
,	O
accelerates	O
intestinal	O
transit	I:C0232484
and	O
decreases	O
accompanying	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
.	O

In	O
chronic	O
constipation	I:C0401149
,	O
lubiprostone	O
improves	O
the	O
frequency	O
of	I:C0426642
BMs	I:C0426642
,	O
softens	O
the	O
stool	B:C0015733
,	O
accelerates	O
intestinal	O
transit	I:C0232484
and	O
decreases	O
accompanying	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
.	O

In	O
chronic	O
constipation	I:C0401149
,	O
lubiprostone	O
improves	O
the	O
frequency	O
of	I:C0426642
BMs	I:C0426642
,	O
softens	O
the	O
stool	O
,	O
accelerates	O
intestinal	B:C0232484
transit	I:C0232484
and	O
decreases	O
accompanying	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
.	O

In	O
chronic	O
constipation	I:C0401149
,	O
lubiprostone	O
improves	O
the	O
frequency	O
of	I:C0426642
BMs	I:C0426642
,	O
softens	O
the	O
stool	O
,	O
accelerates	O
intestinal	O
transit	I:C0232484
and	O
decreases	O
accompanying	O
small	B:C3160854
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
.	O

The	O
improvement	O
of	O
small	B:C3160854
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
could	O
be	O
explained	O
by	O
the	O
cleansing	O
effect	O
of	O
increased	O
intestinal	O
fluid	I:C0232671
and	O
mucus	O
combined	O
with	O
enhanced	O
intestinal	O
motility	I:C0021838
with	O
lubiprostone	O
.	O

The	O
improvement	O
of	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
could	O
be	O
explained	O
by	O
the	O
cleansing	O
effect	O
of	O
increased	O
intestinal	B:C0232671
fluid	I:C0232671
and	O
mucus	O
combined	O
with	O
enhanced	O
intestinal	O
motility	I:C0021838
with	O
lubiprostone	O
.	O

The	O
improvement	O
of	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
could	O
be	O
explained	O
by	O
the	O
cleansing	O
effect	O
of	O
increased	O
intestinal	O
fluid	I:C0232671
and	O
mucus	B:C0026727
combined	O
with	O
enhanced	O
intestinal	O
motility	I:C0021838
with	O
lubiprostone	O
.	O

The	O
improvement	O
of	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
could	O
be	O
explained	O
by	O
the	O
cleansing	O
effect	O
of	O
increased	O
intestinal	O
fluid	I:C0232671
and	O
mucus	O
combined	O
with	O
enhanced	O
intestinal	B:C0021838
motility	I:C0021838
with	O
lubiprostone	O
.	O

The	O
improvement	O
of	O
small	O
intestinal	I:C3160854
bacterial	I:C3160854
overgrowth	I:C3160854
could	O
be	O
explained	O
by	O
the	O
cleansing	O
effect	O
of	O
increased	O
intestinal	O
fluid	I:C0232671
and	O
mucus	O
combined	O
with	O
enhanced	O
intestinal	O
motility	I:C0021838
with	O
lubiprostone	B:C1684405
.	O

